ROLE SUMMARY
We are seeking a candidate specializing in molecular or synthetic biology to work in the BioMedicine Design (BMD) line of the Medicinal Sciences Organization. In this role the candidate will apply molecular and synthetic biology approaches to genome engineering and protein expression in mammalian cell systems for the production of biotherapeutics. The candidate will work with senior scientists within the group to advance biotherapeutic candidates in the discovery space to support the large molecule discovery portfolio across Pfizer.
ROLE RESPONSIBILITIES
* Provide molecular biology support for development of mammalian cell lines stably expressing recombinant protein biotherapeutics.
* Provide cell culture support for pilot expression studies.
* Routinely provide updates at project meetings.
* Proactively evaluate new technologies and implement new features and functionality into the discovery pipeline.
* Work with the head of group, project leads, and other senior group members on experimental design and providing data packages with the goal of identifying and advancing best strategies.
* Successful candidate will be involved in the design and execution of projects with the ability to operate independently.
BASIC QUALIFICATIONS
* BS/MS degree with 5+ years of experience in the area of synthetic biology/bioengineering.
* Extensive hands on experience with a wide range of molecular biology techniques, including design and execution of DNA assembly using strategies such as Gibson and InFusion.
* Experience with gene expression quantification (qPCR, RT-qPCR or ddPCR).
* Experience in mammalian cell culture, genome engineering and stable cell line generation.
* Strong communication skills, written and oral and ability to work in team.
PREFERRED QUALIFICATIONS
* Prior experience with gene therapy is highly desirable.
* Demonstrated knowledge of antibody structure and function is preferred.
* Experience with library design and screening is a plus.
ADDITIONAL INFORMATION
* Eligible for Employee Referral Bonus: Yes
* Last Date to Apply: February 9, 2021
* LI-PFE
Sunshine Act
Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care providers name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.
EEO & Employment Eligibility
Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.
Research and Development
LI-PFE
New York, New York
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names.
Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Pfizer, Merck & Co., Inc., and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.